BioNTech price target raised to $134 from $130 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on BioNTech (BNTX) to $134 from $130 and keeps a Buy rating on the shares. Despite the COVID revenue beat, the firm continues to see risk for long-term adoption. However, it notes that the company is well-positioned to advance the oncology franchise, which BofA sees as “the key long-term driver.”